Cost-Effectiveness of Aducanumab
Sep 01, 2021•3 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Dr. Brian Callaghan discusses the AAN’s comments at a recent ICER meeting on the cost-effectiveness of aducanumab, the newly approved drug for Alzheimer’s disease.
For the best experience, listen in Metacast app for iOS or Android